WHO meeting on preferred product characteristics for monoclonal antibodies for malaria prevention

WHO meeting on preferred product characteristics for monoclonal antibodies for malaria prevention

On 3, 11 and 29 November 2021, the WHO Initiative for Vaccine Research and the Global Malaria Programme convened a Scientific Development Committee to review key issues in product development for monoclonal antibodies (mAbs) for malaria prevention. Experts reviewed and discussed the current landscape of malaria mAbs research and development, priority use case scenarios, and key product development considerations. The aim of the meeting was to develop preferred product characteristics (PPCs) for malaria mAbs.

Specific meeting objectives were to:

1. Review the landscape of malaria mAbs and mAb PPCs for other pathogens.
2. Agree on a set of PPCs for malaria mAbs.
3. Ensure alignment with WHO guidance on mAb development and PPCs for mAbs for other pathogens (HIV, respiratory syncytial virus, coronavirus disease) and complementarity with PPCs for malaria vaccines and chemoprevention.